However, it took until 2020 for a placebo-controlled, double-blind study to be published demonstrating that a KOR antagonist decreased anhedonia, a major symptom of major depressive disorder, in a biomarker-based proof-of-mechanism clinical trial [18]. This evidence concerns the gene OPRK1 and major depressive disorder.